Ask about this productRelated genes to: ApoB protein
- Gene:
- APOB NIH gene
- Name:
- apolipoprotein B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: ApoB protein
Related articles to: ApoB protein
- Homozygous familial hypercholesterolemia (HoFH) is an autosomal genetic disorder that generates increased levels of low-density lipoproteins (LDL) in the serum. Elevated LDL results in hypercholesterolemia leading to potentially fatal cardiovascular disease. HoFH patients are often refractory to standard cholesterol-lowering treatments. Some available pharmaceuticals developed specifically for HoFH can elevate hepatic lipid levels and in other cases have limited accessibility. Previously, we identified a family of triazine thiol compounds that effectively reduce apolipoprotein B-100 (APOB) secretion by hepatocytes. In mice with humanized livers, triazine thiols effectively lowered serum cholesterol, triglycerides, low-density lipoproteins and lipoprotein(a) (Lp(a)). Despite their effectiveness, the mode of action of triazine thiols was unknown. - Source: PubMed
Publication date: 2026/04/28
Blaszkiewicz JosefJiang Yu-LinLiu Jui-TungMartinez-Morant CarlaDearth Troyvan Altena CasperLamprecht Mary PaigeKappler ChristianaLee Mi-HyeBethard Jennifer RBall Lauren EDuncan Stephen A - Hypertensive disorders of pregnancy (HDP) are one of the leading causes of maternal morbidity and death. There is an urgent need to improve early identification of women at risk of HDP, and assessment of pregestational cardiometabolic biomarkers is a potential way forward. - Source: PubMed
Publication date: 2026/04/01
Qvick AngelikaSandström AnnaNorhammar AnnaVikström MaxSpetz Holm Anna-ClaraHultgren RebeckaHammar NiklasLeander Karin - Patients who undergo percutaneous coronary intervention (PCI) remain exposed to residual lipid and inflammatory risk despite contemporary secondary prevention. Real-world longitudinal data describing how conventional lipids, apolipoproteins, small dense low-density lipoprotein (sdLDL), lipoprotein(a) [Lp(a)], and C-reactive protein (CRP) remodel together after PCI are limited. We evaluated serial post-PCI changes in a broad atherosclerotic biomarker panel and explored the dissociation between cholesterol control and inflammatory control. - Source: PubMed
Publication date: 2026/04/30
Wang AnChen ShuaiWang JianyuYin XiangyangDu ChaoyangDing Fenghua - Lipoprotein(a) [Lp(a)] carries cholesterol [Lp(a)-C], yet the cholesterol composition of Lp(a) particles and its relationship to apolipoprotein(a) [apo(a)] isoform size remains incompletely defined. Prior estimates of Lp(a)-C have relied on fixed-percentage assumptions rather than direct biochemical measurement, limiting insight into particle-level heterogeneity. We developed a direct immunocapture assay using the monoclonal antibody LPA4 to quantify Lp(a)-C in plasma and applied it to 94 individuals spanning a wide range of Lp(a) concentrations and apo(a) isoform sizes. Lp(a)-C was strongly correlated with Lp(a) molar concentration (R = 0.925, P < 0.001) and inversely associated with apo(a) isoform size (R = -0.745, P < 0.001). Across tertiles of the predominant apo(a) isoform size, smaller isoforms (12-17 KIV repeats) had higher Lp(a)-C (8.3 ± 4.3 mg/dL; 11.0 ± 3.4%), mid-range isoforms (18-23 KIV) were intermediate (5.0 ± 3.2 mg/dL), whereas larger isoforms (>24 KIV) showed lower Lp(a)-C (3.0 ± 1.5 mg/dL) (P < 0.001). In contrast, particle-normalized metrics demonstrated the opposite pattern: both the Lp(a)-C/Lp(a) molar ratio and Lp(a)-C/Lp(a)-apoB mass ratio increased progressively with apo(a) isoform size (P < 0.001), indicating greater cholesterol content per Lp(a) particle among larger isoforms. These findings demonstrate a dissociation between circulating Lp(a)-C concentration, which primarily reflects particle number, and cholesterol content per particle, which varies systematically with apo(a) isoform size. Direct measurement of Lp(a)-C identifies compositional heterogeneity not captured by conventional estimation methods and may provide a framework for future studies of isoform-dependent variation in Lp(a) structure and function. - Source: PubMed
Publication date: 2026/04/27
Tsimikas SotiriosMarcovina Santica M - To evaluate the efficacy of obicetrapib combination therapy group against the obicetrapib alone or placebo arm. - Source: PubMed
Publication date: 2026/04/28
Nawaz MHassan Zafar MIbrahim Smeak RRab Nawaz SAhmad BTimsina GAndleeb BWaheed NHammad Arif MAhmad Khan U